Also Type 2 diabetes that Intarcia hopes to treat with its stabilized Exenatide contained in its implant---note the shelf life emphasized by Graves. FDA filing expected later this year.
A lot of history here. JNJ, Amylin, BMY and now AZN in the background? What is the present story behind older charges of infringement of the Exenatide patent portfolio by the stabilized Intarcia molecule?
Market Data 
Markets 
AI
